Study advises RSV therapies for infants target virus and immune response

Researchers at University College London and Great Ormond Street Hospital for Children have published a study indicating that effective future treatments for respiratory syncytial virus (RSV) will need to address both the virus itself and the host immune response. The findings suggest that targeting only viral replication or solely modulating inflammation may be insufficient to achieve optimal outcomes for infants, who are the most vulnerable group.

The study, which involved collaboration between virology and immunology teams at UCL and GOSH, highlights the complex interplay between RSV infection and the developing immune system. By demonstrating that dual‑mechanism approaches can more comprehensively reduce viral load and mitigate harmful inflammatory responses, the research provides a framework for designing next‑generation therapeutics that could improve survival and reduce long‑term respiratory complications in newborns.

These insights are expected to guide clinical trial design and drug development strategies, emphasizing the importance of integrated antiviral and immunomodulatory interventions. The authors call for continued investment in research that bridges virology and immunology to deliver safer, more effective RSV therapies for the most at‑risk pediatric populations.